Clarification on the news article by Commercial TimesJuly 30, 2018
OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink SecuritiesSeptember 3, 2018
- Date of occurrence of the event: Aug 15, 2018
- Company name: OBI Pharma Inc.
- Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
- Reciprocal shareholding ratios: N/A
- Cause of occurrence: OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia (No. 2016229136).
- Countermeasures: None
- Any other matters that need to be specified: None